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SUMMARY. Formulation and in vitro evaluation of losartan potassium (LP) loaded transdermal delivery
system (TDS) was investigated for controlled release and improved therapeutic efficacy. TDS (patches)
were prepared by varying the composition of Eudragit RL 100 and Eudragit RS 100 (5:0, 4:1, 3:2, 2.5:2.5,
2:3, 1:4 and 0:5). Patches were evaluated for thickness, content uniformity, mechanical properties, mois-
ture uptake and in vitro drug release. Technological parameters for all the formulations were found to be
within the limit. In vitro studies showed relatively high permeation of LP (F1- 42.17 ± 1.13 %) from the
formulation comprising 4:1 ratio of polymer. Inclusion of capsaicin (55.70 ± 1.55 %) and pluronic F-68
(70.88 ± 1.20 %) to formulation F1 resulted increased permeation of LP across human skin. In conclusion,
this study demonstrated the potential of simple transdermal adhesive patch incorporating LP to deliver
therapeutically useful dose in-vivo for the treatment of hypertension. 
